Potencjał bioterapeutyczny technologii RNAi

• Authors: Przemysław Sołek , Aleksandra Maziarz , Marek Koziorowski

Title variants

EN

Biotherapeutic potential of RNAi technology

• Languages of publication: PL EN

Abstracts

PL

W ciągu ostatnich lat zjawisko interferencji RNA (RNAi) stało się powszechnie wykorzystywane jako eksperymentalne narządzie do analizy genów oraz pełnionych przez nie funkcji. Wraz ze wzrostem wiedzy na temat molekularnych mechanizmów działania endogennego interferującego RNA, małe interferujące RNA (siRNA), mogą pojawić się jako grupa innowacyjnych bioleków stosowanych do leczenia wielu chorób m.in. chorób nowotworowych. Poznanie i zrozumienie szlaków molekularnych istotnych w procesie nowotworzenia stwarza możliwości dla terapii nowotworowej wykorzystującej mechanizm RNAi. Nowe terapie w leczeniu nowotworów są niezbędne, a wykorzystanie małych interferujących RNA może stanowić realną strategię.

EN

In the last few years, RNA interference (RNAi) has become widely used as an experimental tool for the analyses of genes and their functions. With increasing knowledge about the molecular mechanisms of function of endogenous RNA interference, small interfering RNA (siRNA), may occur as innovative bio-drugs for treatment of diseases such as cancer. Knowledge and understanding of the molecular pathways important for carcinogenesis create opportunities for cancer therapy using RNAi mechanism. New therapies are essential for tumors treatment, and small interfering RNAs may provide a viable strategy.

Keywords

PL

mechanizm RNAi; siRNA; terapia nowotworowa; wyciszanie genów

• Journal: Kosmos
• Year: 2016
• Volume: 65
• Issue: 1
• Pages: 17-22

Dates

published

2016

Contributors

author

Przemysław Sołek

• Instytut Biotechnologii Stosowanej i Nauk Podstawowych, Uniwersytet Rzeszowski, Werynia 502; 36-100 Kolbuszowa, Polska
• Institute of Applied Biotechnology and Basic Sciences, University of Rzeszow, Werynia 502, 36-100 Kolbuszowa, Poland
• Centrum Biotechnologii Stosowanej i Nauk Podstawowych, Uniwersytet Rzeszowski, Werynia 502; 36-100 Kolbuszowa, Polska
• Centre of Applied Biotechnology and Basic Sciences, University of Rzeszow, Werynia 502, 36-100 Kolbuszowa, Poland

author

Aleksandra Maziarz

• Wydział Medyczny, Przyrodnioczo-Medyczne Centrum Badań Innowacyjnych, Uniwersytet Rzeszowski, Warzywna 1a; 35-310 Rzeszów, Polska
• Faculty of Medicine, Centre for Innovative Research in Medical and Natural Sciences, University of Rzeszow, Warzywna 1a; 35-310 Rzeszów, Poland

author

Marek Koziorowski

• Instytut Biotechnologii Stosowanej i Nauk Podstawowych, Uniwersytet Rzeszowski, Werynia 502; 36-100 Kolbuszowa, Polska
• Institute of Applied Biotechnology and Basic Sciences, University of Rzeszow, Werynia 502, 36-100 Kolbuszowa, Poland
• Centrum Biotechnologii Stosowanej i Nauk Podstawowych, Uniwersytet Rzeszowski, Werynia 502; 36-100 Kolbuszowa, Polska
• Centre of Applied Biotechnology and Basic Sciences, University of Rzeszow, Werynia 502, 36-100 Kolbuszowa, Poland

References

• Angaji S. A., Hedayati S. S., Poor R. H., Madani S., Poor S. S., Panahi S., 2010. Application of RNA interference in treating human diseases. J. Genet. 4, 527-537.
• Bovenberg M. S., Degeling M. H., Tannous B. A., 2013. Advances in stem cell therapy against gliomas. Trends Mol. Med. 19, 281-291.
• Campbell T. N., Choy F. Y., 2005. RNA interference: past, present and future. Curr. Issues Mol. Biol. 1, 1-6.
• Catuogno S. S., Esposito C. L., Quintavalle C., Condorelli G., Franciscis V., Cerchia L., 2012. Nucleic acids in human glioma treatment: innovative approaches and recent results. J. Signal Transd. http://dx.doi.org/10.1155/2012,735135.
• Cejka D., Losert D., Wacheck V., 2006. Short interfering RNA (siRNA): tool or therapeutic? Clin. Sci. 1, 47-58.
• Choi K. Y., Silvestre O. F., Huang X., Min K. H., Howard G. P., Hida N., Jin A. J., Carvajal N., Lee S. W., Hong J. I., Chen X., 2014. Vesatile RNA interference nanoplatform for systemic delivery of RNAs. ASC Nano 8, 4559-4570.
• Davidson B. L., McCray P. B., 2011. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329-340.
• Fellmann C., Lowe S. W., 2014. Stable RNA interference rules for silencing. Nat. Cell Biol. 16, 10-18.
• Gartel A. L., Kandel E. S., 2006. RNA interference in cancer. Biomol. Engin. 1, 17-34.
• Gavrilov K., Saltzman W. M., 2012. Therapeutic siRNA: principles, challenges, and strategies. Yale J. Biol. Med. 85, 187-200.
• Germano I. M., Binello E., 2013. Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J. Neuro-Oncol. 93, 79-87.
• Grimm D., Kay M., 2007. RNAi and gene therapy: a mutual attraction. Hematology 473-481.
• Kozielski K. L., Tzeng S. Y., Green J. J., 2013. Bioengineered nanoparticles for siRNA delivery. WIREs Nanomed. Nanobiotechnol. 5, 449-468.
• Lage H., 2005. Potential applications of RNA interference technology in the treatment of cancer. Future Oncol. 1, 103-113.
• Lares M. R., ROSSI J. J., OUELLET D. L., 2010. RNAi and small interfering RNAs in human diesease therapeutic application. Trends Biotechnol. 28, 570-579.
• Lei C., Cui Y., Zheng L., Kah-Hoe Chow P., Wang C. H., 2013. Development of a gene/drug dual delivery system for brain tumor therapy: Potent inhibition via RNA interference and synergistic effects. Biomaterials 30, 7483-7494.
• Leung R. K., Whittaker P. A., 2005. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Therapeut. 2, 222-239.
• Li C. X., Parker A., Menocal E., Xiang S., Borodyansky L., Fruehauf J. H., 2006. Delivery of RNA interference. Cell Cycle 18, 2103-2109.
• Liu B., Wang L., Shen L. L., Shen M. Z., Guo X. D., Wang T., Liang Q. C., Wang C., Zheng J., Li Y., Jia L. T., Zhang H., Gao G. D., 2013. RNAi-mediated inhibition of presenilin 2 inhibits glioma cell growth and invasion and is involved in the regulation of Nrg1/ErbB signaling. Neuro-Oncol. 14, 994-1006.
• Mansoori B., Shotorbani S. S., Baradaran B., 2014. RNA interference and its role in cancer therapy. Adv. Pharmaceut. Bull. 4, 313-321.
• Medema R. H., 2004. Optimizing RNA interference for application in mammalian cells. Biochem. J. 3, 593-603.
• Mittal V., 2004. Improving the efficiency of RNA interference in mammals. Nat. Rev. Genet. 5, 355-65.
• Oh Y. K., Park T. G., 2009. siRNA delivery systems for cancer treatment. Adv. Drug Del. Rev. 10, 850-862.
• Pai S. I., Lin Y. Y., Macaes B., Meneshian A., Hung C. F., Wu T. C., 2006. Prospects of RNA interference therapy for cancer. Gene Therap. 6, 464-477.
• Rème T., Hugnot J. P., Bièche I., Rigau V., Burel-Vandenbos F., Prévot V., Baroncini M., Fontaine D., Chevassus H., Vacher S., Lidereau R., Duffau H., Bauchet L., Joubert D., 2013. A molecular predictor reassesses classification of human grade II/III Gliomas. PLoS ONE 6, e66574.
• Rochlitz C. F., 2001. Gene therapy of cancer. Swiss Med. Weekly 131, 4-9.
• Svoboda P., 2013. Renaissance of mammalian endogenous RNAi. FEBS Lett. 588, 2550-2556.
• Takeshita F., Ochiya T., 2006. Therapeutic potential of RNA interference against cancer. Cancer Sci. 8, 689-696.
• Tsai W. H., Chang W. T., 2014. Construction of simple and efficient siRNA validation systems for screening and identification of effective RNAi-targeted sequences from mammalian genes. Meth. Mol. Biol. 1101, 321-338.
• Vile R. G., Russell S. J., Lemoine N. R., 2000. Cancer gene therapy: hard lessons and new courses. Gene Therap. 1, 2-8.
• Wasi S., 2003. RNA interference: the next genetics revolution? Nature Publishing Group http://www.nature.com/horizon/rna/background/interference.html.
• Yang Y. L., Chang W. T., Shih Y. W., 2011. Gene therapy using RNAi. [W:] Gene Therapy - Developments and Future Perspectives. Kang C. (red.). Chung Hwa University of Medical Technology, InTech, 31-52.
• Younis A., Siddique M. I., Kim C. K., Lim K. B., 2014. RNA interference (RNAi) induced gene silencing: a promising approach of hi-tech plant breeding. Int. J. Biol. Sci. 10, 1150-1158.